Watch our webinar “How are costs and medicine effectiveness part of decision-making in medicine access?”Access, Videos15 October 2025
EMA CHMP gives positive opinion on daratumumab use in smouldering myeloma patients with high risk of developing myelomaAccess, Myeloma27 June 2025
EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patientsAccess, Myeloma28 May 2025
European Commission approves linvoseltamab for the treatment of relapsed and refractory myelomaAccess, Myeloma29 April 2025
Register now to join the webinar ‘How do different countries make decisions on reimbursing new medicines?’Access, MPE6 March 2025
EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patientsAccess, Myeloma, News3 March 2025
The European Commission approves isatuximab + VRd combination therapy for newly diagnosed, transplant ineligible myeloma patientsAccess, Myeloma, News24 January 2025
Myeloma and AL amyloidosis ASH 2024 previewAccess, AL amyloidosis, CAR-T, MPE, Myeloma29 November 2024
